Navigation Links
Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
Date:9/17/2009

HAYWARD, Calif., Sept. 17 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide. Building upon the successful completion of a 28-day phase 1b study of ITCA 650 in May of this year, the phase 2 study is intended to evaluate the doses achieving the best results in the phase 1b in a larger study population and for a longer duration of treatment. In addition, an extension phase of the phase 2 study will evaluate dose response of ITCA 650. Patients receiving Byetta for the first 12 weeks will be switched from Byetta to one of two doses of ITCA 650 to evaluate the potential for improving treatment effect.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

"We are very pleased with the rapid progress and positive results achieved thus far in the ITCA 650 program" said Ken Luskey, MD, VP, Clinical Research for Intarcia. "In 2009, we expect to move the ITCA 650 program from IND-filing through completion of phase 2 enrollment."

The ITCA 650 phase 2 study will involve 150 patients with sub-optimally controlled type 2 diabetes treated with metformin. Patients will be recruited at 50 clinical trial sites in the US and will be randomized equally to receive one of two doses of ITCA 650 or twice-daily injections of Byetta. Upon completion of the 12-week course of treatment, patients on all three arms will be further randomized to receive higher doses of ITCA 650 for an additional 12 weeks. The extension phase will evaluate efficacy and tolerability of higher doses of ITCA 650, as well as the effects of switching patients from twice-daily injec
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
7. Nile Therapeutics, Inc. Adds to Executive Management Team
8. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
9. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
10. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that it ... Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is an ... and how agriculture impacts their daily lives. This unique exhibit also features a birthing ...
(Date:7/30/2015)... Dallas, TX, USA (PRWEB) , ... July 30, ... ... nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... 2 to 3 children in 100 are born with a ... but in 80% of the cases scientists do not know ... Katholieke Universiteit Leuven, in collaboration with an Australian research team, ... mental retardation is caused by a twofold production of two ...
... Jan. 24 Cardica, Inc.,(Nasdaq: CRDC ) ... fiscal 2008 second quarter and six months ended ... excellent commercial progress, with over 1,000,C-Port systems shipped ... an expanding,product line designed to enable minimally-invasive cardiac ...
... Defined Structure Synthesized,in the Lab, Team Completes Second ... ROCKVILLE, Md., Jan. 24 A team of 17,researchers ... the largest,man-made DNA structure by synthesizing and assembling the ... This work, published,online today in the journal Science by ...
Cached Biology Technology:Discovery of new cause of mental retardation simplifies search for treatments 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Venter Institute Scientists Create First Synthetic Bacterial Genome 2Venter Institute Scientists Create First Synthetic Bacterial Genome 3Venter Institute Scientists Create First Synthetic Bacterial Genome 4Venter Institute Scientists Create First Synthetic Bacterial Genome 5Venter Institute Scientists Create First Synthetic Bacterial Genome 6
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... plants supplement the meager diet available from the nutrient-poor ... insects and other small arthropods. Pitcher plants of the ... a simple passive trap but in a paper in ... a biologist and a physicist from the CNRS, working ...
... University center that aims to improve crop production by ... of continued and expanded support from the Monsanto Company, ... will fund student exchanges and a series of plant ... for Plant Molecular Genetics and Agrobiotechnology , a multidisciplinary ...
... emissions from using coal are set to double by 2030, ... global climate change. In view of the essential role of ... where coal is used. The British Geological Survey ... Phase 1 study in Beijing, China today. The aim of this ...
Cached Biology News:Carnivorous plants use pitchers of 'slimy saliva' to catch their prey 2Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2UK scientists lead China closer to carbon capture and storage 2
Cell Culture Flask, 75 cm, treated polystyrene...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
... of amino acids and peptides produced ... It is recommended for laboratory media ... in antibiotics, toxins and enzyme productions. ... pH6.8 0.5 at 25 C, 2% ...
... Human Raji cells were cultured in RPMI 1640 ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Biology Products: